128 related articles for article (PubMed ID: 23020605)
21. Y-box binding protein-1 expression in diffuse large B-cell lymphoma: an impact on prognosis in the rituximab era.
Hanzawa K; Momose S; Higashi M; Tokuhira M; Watanabe R; Kajino K; Hino O; Itoyama S; Kizaki M; Tamaru J
Leuk Lymphoma; 2010 Nov; 51(11):2054-62. PubMed ID: 20929326
[TBL] [Abstract][Full Text] [Related]
22. Prognostic value of hypoxia-inducible factor-1 alpha and prolyl 4-hydroxylase beta polypeptide overexpression in gastric cancer.
Zhang J; Wu Y; Lin YH; Guo S; Ning PF; Zheng ZC; Wang Y; Zhao Y
World J Gastroenterol; 2018 Jun; 24(22):2381-2391. PubMed ID: 29904245
[TBL] [Abstract][Full Text] [Related]
23. Association between the expression of HIF-1α and VEGF and prognostic implications in primary liver cancer.
Guo LY; Zhu P; Jin XP
Genet Mol Res; 2016 May; 15(2):. PubMed ID: 27173353
[TBL] [Abstract][Full Text] [Related]
24. Clinicopathological significance of hypoxia-inducible factor-1 alpha (HIF-1α) expression in gastric cancer.
Isobe T; Aoyagi K; Koufuji K; Shirouzu K; Kawahara A; Taira T; Kage M
Int J Clin Oncol; 2013 Apr; 18(2):293-304. PubMed ID: 22350022
[TBL] [Abstract][Full Text] [Related]
25. Hypoxia-Inducible Factor-1α (HIF-1α) Expression on Endothelial Cells in Juvenile Nasopharyngeal Angiofibroma: A Review of 70 cases and Tissue Microarray Analysis.
Song X; Yang C; Zhang H; Wang J; Sun X; Hu L; Liu Z; Wang D
Ann Otol Rhinol Laryngol; 2018 Jun; 127(6):357-366. PubMed ID: 29717655
[TBL] [Abstract][Full Text] [Related]
26. Prognostic effect of Ki-67 expression in rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone-treated diffuse large B-cell lymphoma is limited to non-germinal center B-cell-like subtype in late-elderly patients.
Koh YW; Hwang HS; Park CS; Yoon DH; Suh C; Huh J
Leuk Lymphoma; 2015; 56(9):2630-6. PubMed ID: 25573205
[TBL] [Abstract][Full Text] [Related]
27. Effect of endothelial PAS domain protein 1 and hypoxia inducible factor 1alpha on vascular endothelial growth factor expression in human pancreatic carcinoma.
Zhu DM; Li DC; Zhang ZX; Zhang XY
Chin Med J (Engl); 2008 Nov; 121(22):2258-64. PubMed ID: 19080330
[TBL] [Abstract][Full Text] [Related]
28. Matched-pair analysis comparing the outcomes of primary breast and nodal diffuse large B-cell lymphoma in patients treated with rituximab plus chemotherapy.
Yhim HY; Kim JS; Kang HJ; Kim SJ; Kim WS; Choi CW; Eom HS; Kim JA; Lee JH; Won JH; Shim H; Huh J; Lee DH; Suh C; Kwak JY
Int J Cancer; 2012 Jul; 131(1):235-43. PubMed ID: 21823120
[TBL] [Abstract][Full Text] [Related]
29. Upregulation of hypoxia-inducible factor-1alpha mRNA and its clinical significance in non-small cell lung cancer.
Yohena T; Yoshino I; Takenaka T; Kameyama T; Ohba T; Kuniyoshi Y; Maehara Y
J Thorac Oncol; 2009 Mar; 4(3):284-90. PubMed ID: 19190516
[TBL] [Abstract][Full Text] [Related]
30. The association of genetic polymorphisms of hypoxia inducible factor-1 alpha and vascular endothelial growth factor with increased risk of chronic obstructive pulmonary disease: A case-control study.
Yu ZG; Wang BZ; Cheng ZZ
Kaohsiung J Med Sci; 2017 Sep; 33(9):433-441. PubMed ID: 28865600
[TBL] [Abstract][Full Text] [Related]
31. High Ki-67 expression in involved bone marrow predicts worse clinical outcome in diffuse large B cell lymphoma patients treated with R-CHOP therapy.
Song MK; Chung JS; Lee JJ; Yang DH; Kim IS; Shin DH; Shin HJ
Int J Hematol; 2015 Feb; 101(2):140-7. PubMed ID: 25504496
[TBL] [Abstract][Full Text] [Related]
32. Gray zone lymphoma with features intermediate between classical Hodgkin lymphoma and diffuse large B-cell lymphoma: characteristics, outcomes, and prognostication among a large multicenter cohort.
Evens AM; Kanakry JA; Sehn LH; Kritharis A; Feldman T; Kroll A; Gascoyne RD; Abramson JS; Petrich AM; Hernandez-Ilizaliturri FJ; Al-Mansour Z; Adeimy C; Hemminger J; Bartlett NL; Mato A; Caimi PF; Advani RH; Klein AK; Nabhan C; Smith SM; Fabregas JC; Lossos IS; Press OW; Fenske TS; Friedberg JW; Vose JM; Blum KA
Am J Hematol; 2015 Sep; 90(9):778-83. PubMed ID: 26044261
[TBL] [Abstract][Full Text] [Related]
33. Clinicopathologic implication of A20/TNFAIP3 deletion in diffuse large B-cell lymphoma: an analysis according to immunohistochemical subgroups and rituximab treatment.
Paik JH; Go H; Nam SJ; Kim TM; Heo DS; Kim CW; Jeon YK
Leuk Lymphoma; 2013 Sep; 54(9):1934-41. PubMed ID: 23327292
[TBL] [Abstract][Full Text] [Related]
34. Vascular endothelial growth factor (VEGF) and hypoxia inducible factor-1 alpha (HIF-1ɑ) in lacrimal gland Adenoid cystic carcinoma: Correlation with clinical outcome.
Anjum S; Sen S; Chosdol K; Bakhshi S; Kashyap S; Pushker N; Bajaj MS; Meel R; Sharma MC
Ann Diagn Pathol; 2022 Feb; 56():151846. PubMed ID: 34749048
[TBL] [Abstract][Full Text] [Related]
35. Overexpression of hypoxia inducible factor-1 alpha is an independent risk factor for recurrence after curative resection of colorectal liver metastases.
Shimomura M; Hinoi T; Kuroda S; Adachi T; Kawaguchi Y; Sasada T; Takakura Y; Egi H; Okajima M; Tashiro H; Nishizaka T; Ohdan H
Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S527-36. PubMed ID: 23748663
[TBL] [Abstract][Full Text] [Related]
36. CD99 expression and newly diagnosed diffuse large B-cell lymphoma treated with rituximab-CHOP immunochemotherapy.
Hong J; Park S; Park J; Jang SJ; Ahn HK; Sym SJ; Cho EK; Shin DB; Lee JH
Ann Hematol; 2012 Dec; 91(12):1897-906. PubMed ID: 22864685
[TBL] [Abstract][Full Text] [Related]
37. Hypoxia inducible factor-1alpha correlates with vascular endothelial growth factor A and C indicating worse prognosis in clear cell renal cell carcinoma.
Dorević G; Matusan-Ilijas K; Babarović E; Hadzisejdić I; Grahovac M; Grahovac B; Jonjić N
J Exp Clin Cancer Res; 2009 Mar; 28(1):40. PubMed ID: 19302703
[TBL] [Abstract][Full Text] [Related]
38. Young patients with non-germinal center B-cell-like diffuse large B-cell lymphoma benefit from intensified chemotherapy with ACVBP plus rituximab compared with CHOP plus rituximab: analysis of data from the Groupe d'Etudes des Lymphomes de l'Adulte/lymphoma study association phase III trial LNH 03-2B.
Molina TJ; Canioni D; Copie-Bergman C; Recher C; Brière J; Haioun C; Berger F; Fermé C; Copin MC; Casasnovas O; Thieblemont C; Petrella T; Leroy K; Salles G; Fabiani B; Morschauser F; Mounier N; Coiffier B; Jardin F; Gaulard P; Jais JP; Tilly H
J Clin Oncol; 2014 Dec; 32(35):3996-4003. PubMed ID: 25385729
[TBL] [Abstract][Full Text] [Related]
39. Clinical significance of nuclear factor κB and chemokine receptor CXCR4 expression in patients with diffuse large B-cell lymphoma who received rituximab-based therapy.
Shin HC; Seo J; Kang BW; Moon JH; Chae YS; Lee SJ; Lee YJ; Han S; Seo SK; Kim JG; Sohn SK; Park TI
Korean J Intern Med; 2014 Nov; 29(6):785-92. PubMed ID: 25378977
[TBL] [Abstract][Full Text] [Related]
40. [Expression of hypoxia-inducible factor-1alpha and vessel endothelial growth factor in esophageal squamous cell carcinoma and clinico-pathological significance thereof].
Yu ZT; Zhao HF; Shang XB
Zhonghua Yi Xue Za Zhi; 2008 Sep; 88(35):2465-9. PubMed ID: 19080625
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
